Physical activity and associations with treatment-induced adverse effects among prostate cancer patients
The present study aimed to determine the level of physical activity (PA) among prostate cancer (PCa) patients across treatment modalities and explore the association between PA and treatment-induced adverse effects (AEs).
The present study was based on a cross-sectional postal survey among members of the Norwegian Prostate Cancer Association. Patients were eligible for the present study if they had either (1) completed radical prostatectomy, (2) completed radiotherapy and (neo)-adjuvant androgen deprivation therapy (ADT), or (3) were undergoing lifelong ADT. Adverse effects were measured by the Expanded Prostate Cancer Index Composite for Clinical Practice.
In total, 696 patients were included. There was no statistically significant difference in level of PA across treatment modalities. Bowel symptoms mainly related to radiotherapy decreased the odds of exercising ≥ 2 times per week, along with age ≥ 70 years, participation in the workforce, and BMI ≥ 25 kg/m2. Among patients who were undergoing ADT, 5 years or more since diagnosis reduced the odds of exercising ≥ 2 times per week by almost 60%.
The level of PA did not differ across PCa patients treated with different modalities. Increasing bowel symptoms reduced the likelihood of exercising ≥ 2 times per week. PCa patients should be educated about possible treatment-induced AEs affecting PA level, enabling them to counteract the development of physical inactivity.
KeywordsProstate cancer Physical activity Treatment-induced adverse effects Radiotherapy Androgen deprivation therapy Prostatectomy
This study was funded by the Norwegian Cancer Society (project no. 45980 – Norwegian Consortium on Late Effects after Cancer).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2012) Global Cancer statistics. CA Cancer J Clin 2015:87–108Google Scholar
- 2.Cancer Registry of Norway (2017) Cancer in Norway 2016 - Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway, OsloGoogle Scholar
- 3.Solberg A, Angelsen A, Berge V (2013) Nasjonalt handlings program med retningslinjer for diagnostikk, behandling og oppfølging av prostatakreft. Oslo, HelsedirektoratetGoogle Scholar
- 6.Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250–1261CrossRefPubMedGoogle Scholar
- 14.Galvao DA, Newton RU, Gardiner RA, Girgis A, Lepore SJ, Stiller A et al (2015) Compliance to exercise-oncology guidelines in prostate cancer survivors and associations with psychological distress, unmet supportive care needs, and quality of life. Psycho-oncology 24(10):1241–9 Google Scholar
- 24.Fossa SD, Dahl AA (2015) Global quality of life after curative treatment for prostate cancer: what matters? A study among members of the Norwegian prostate cancer patient association. Clin Genitourin Cancer 13(6):518–24 Google Scholar
- 26.Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC et al (2011) Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 186(3):865–872CrossRefPubMedGoogle Scholar
- 27.Szymanski KM, Wei JT, Dunn RL, Sanda MG (2010) Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 76(5):1245–50 Google Scholar
- 28.Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM et al (2014) Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol 191(3):638–45Google Scholar
- 29.Tsumura H, Satoh T, Ishiyama H, Hirano S, Tabata K, Kurosaka S, Matsumoto K, Fujita T, Kitano M, Baba S, Hayakawa K, Iwamura M (2015) Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy. World J Radiol 7(12):494–500CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Hansen BH, Kolle E, Anderssen SA (2014) Fysisk aktivitetsnivå blant voksne og eldre i Norge Oppdaterte analyser basert på nye nasjonale anbefalinger i 2014. Oslo, HelsedirektoratetGoogle Scholar
- 35.Nelson AM, Gonzalez BD, Jim HS, Cessna JM, Sutton SK, Small BJ, Fishman MN, Zachariah B, Jacobsen PB (2016) Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer 24(10):4159–4166CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Kampshoff CS, Stacey F, Short CE, van Mechelen W, Chinapaw MJM, Brug J, Plotnikoff R, James EL, Buffart LM (2016) Demographic, clinical, psychosocial, and environmental correlates of objectively assessed physical activity among breast cancer survivors. Support Care Cancer 24:3333–3342CrossRefPubMedPubMedCentralGoogle Scholar